3,357 Shares in Glaukos Corporation $GKOS Acquired by United Services Automobile Association

Key Points

• United Services Automobile Association purchased a new stake in Glaukos Corporation, acquiring 3,357 shares valued at approximately $342,000 in the first quarter.
• Glaukos reported a 29.7% increase in quarterly revenue year-over-year, amounting to $124.12 million, despite posting a loss of ($0.24) earnings per share.
• Analyst opinions vary, with several rating Glaukos as a "Moderate Buy" and a consensus price target of $124.83.

United Services Automobile Association purchased a new stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 3,357 shares of the medical instruments supplier's stock, valued at approximately $342,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of GKOS. Bessemer Group Inc. increased its stake in Glaukos by 133.9% during the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock valued at $27,000 after purchasing an additional 158 shares in the last quarter. Whipplewood Advisors LLC boosted its holdings in shares of Glaukos by 3,957.1% in the 1st quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock worth $28,000 after buying an additional 277 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in shares of Glaukos by 72.9% in the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock worth $37,000 after buying an additional 159 shares during the last quarter. Versant Capital Management Inc boosted its holdings in shares of Glaukos by 583.9% in the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock worth $38,000 after buying an additional 327 shares during the last quarter. Finally, Bayforest Capital Ltd purchased a new position in shares of Glaukos in the 1st quarter worth about $141,000. Institutional investors own 99.04% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. William Blair raised shares of Glaukos to a "strong-buy" rating in a report on Thursday, July 31st. BTIG Research reaffirmed a "buy" rating and set a $118.00 price objective on shares of Glaukos in a report on Wednesday, September 10th. UBS Group upped their price objective on shares of Glaukos from $125.00 to $134.00 and gave the company a "buy" rating in a report on Thursday, July 31st. Wells Fargo & Company upped their price objective on shares of Glaukos from $86.00 to $92.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. Finally, Mizuho set a $130.00 price objective on shares of Glaukos in a report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $124.83.

Glaukos Price Performance

Shares of Glaukos stock traded down $2.04 on Monday, reaching $80.72. The stock had a trading volume of 1,211,730 shares, compared to its average volume of 932,516. Glaukos Corporation has a 1 year low of $77.10 and a 1 year high of $163.71. The company has a market cap of $4.63 billion, a P/E ratio of -48.92 and a beta of 0.77. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. The business's 50 day moving average is $93.48 and its two-hundred day moving average is $95.49.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The firm had revenue of $124.12 million for the quarter, compared to the consensus estimate of $115.49 million. During the same period in the prior year, the firm posted ($0.52) earnings per share. The company's revenue for the quarter was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.